• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    2/13/24 10:12:25 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHVS alert in real time by email
    SC 13G/A 1 eh240447464_13ga2-pharvaris.htm AMENDMENT NO. 2

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Pharvaris N.V.
    (Name of Issuer)
     
    Ordinary shares, par value €0.01 per share
    (Title of Class of Securities)
     
    N69605108
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 2 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 3 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic PH B.V.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    The Netherlands

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 4 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Coöperatief U.A.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    The Netherlands

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 5 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Bermuda) IV, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 6 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Bermuda) EU, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 7 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Lux) SCSp

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 8 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Coöperatief, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 9 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments III, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 10 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments IV, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 11 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments V, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 12 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments CDA, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 13 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic GenPar, (Lux) SCSp

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 14 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic (Lux) S.à r.l.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 15 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic GenPar (Bermuda), L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 16 of 26

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP (Bermuda) L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    7,531,252

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    7,531,252

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,531,252

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    14.1%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 17 of 26

     

     

    Item 1. (a) NAME OF ISSUER
         
        Pharvaris N.V. (the “Company”).
         
      (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
         
        Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands
         
    Item 2. (a) NAMES OF PERSONS FILING

     

    This Statement is being filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

      (i) General Atlantic, L.P. (“GA LP”);
         
      (ii) General Atlantic PH B.V. (“GA PH”);
         
      (iii) General Atlantic Coöperatief U.A. (“GA Coop UA”);
         
      (iv) General Atlantic Partners (Bermuda) IV, L.P. (“GAP Bermuda IV”);
         
      (v) General Atlantic Partners (Bermuda) EU, L.P. (“GAP Bermuda EU”);
         
      (vi) General Atlantic Partners (Lux) SCSp (“GAP Lux”);
         
      (vii) General Atlantic Coöperatief, L.P. (“GA Coop LP”);
         
      (viii) GAP Coinvestments III, LLC (“GAPCO III”);
         
      (ix) GAP Coinvestments IV, LLC (“GAPCO IV”);
         
      (x) GAP Coinvestments V, LLC (“GAPCO V”);
         
      (xi) GAP Coinvestments CDA, L.P. (“GAPCO CDA”);
         
      (xii) General Atlantic GenPar, (Lux) SCSp (“GA GenPar Lux”);
         
      (xiii) General Atlantic (Lux) S.à r.l. (“GA Lux”);
         
      (xiv) General Atlantic GenPar (Bermuda), L.P. (“GenPar Bermuda”); and
         
      (xv) GAP (Bermuda) L.P. (“GAP (Bermuda) LP”).

    GAP (Bermuda) IV, GAP (Bermuda) EU, GAP Lux and GA Coop LP are collectively referred to as the “GA Funds.” GAPCO III, GAPCO IV, GAPCO V and GAPCO CDA are collectively referred to as the “Sponsor Coinvestment Funds.”

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 18 of 26

     

     

      (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE

     

    The address of GA Coop LP, GAP Bermuda IV, GAP Bermuda EU, GenPar Bermuda, and GAP (Bermuda) LP is c/o Conyers Client Services (Bermuda) Limited, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The address of GA PH and GA Coop UA is c/o General Atlantic, Prinsengracht 769, Amsterdam, 1017 JZ The Netherlands. The address of GAP Lux, GA GenPar Lux and GA Lux is 412F Route d’Esch, L-1471 Luxembourg. The address of GA LP and each of the Sponsor Coinvestment Funds is c/o General Atlantic Service Company, L.P., 55 East 52nd Street, 33rd Floor, New York, NY 10055.

      (c) CITIZENSHIP
         
      (i) GA LP – Delaware
         
      (ii) GA PH – The Netherlands
         
      (iii) GA Coop UA - The Netherlands
         
      (iv) GAP Bermuda IV - Bermuda
         
      (v) GAP Bermuda EU – Bermuda
         
      (vi) GAP Lux - Luxembourg
         
      (vii) GA Coop LP - Bermuda
         
      (viii) GAPCO III - Delaware
         
      (ix) GAPCO IV - Delaware
         
      (x) GAPCO V - Delaware
         
      (xi) GAPCO CDA - Delaware
         
      (xii) GA GenPar Lux - Luxembourg
         
      (xiii) GA Lux - Luxembourg
         
      (xiv) GenPar Bermuda - Bermuda
         
      (xv) GAP (Bermuda) LP – Bermuda

     

      (d) TITLE OF CLASS OF SECURITIES

     

    Ordinary shares, par value €0.12 per share (the “ordinary shares”)

      (e) CUSIP NUMBER

     

    N69605108

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 19 of 26

     

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS:

     

    Not applicable.

     

    Item 4. OWNERSHIP.

     

    As of January 25, 2024, the Reporting Persons owned the following number of the Company’s common stock:

      (i) GA LP owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (ii)

    GA PH owned of record 7,531,252 ordinary shares or 14.1% of the issued and outstanding ordinary shares

         
      (iii) GA Coop UA owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (iv) GAP Bermuda IV owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (v) GAP Bermuda EU owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (vi) GAP Lux owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (vii) GA Coop LP owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (viii) GAPCO III owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (ix) GAPCO IV owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (x) GAPCO V owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (xi) GAPCO CDA owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (xii) GA GenPar Lux owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (xiii) GA Lux owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (xiv) GenPar Bermuda owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares
         
      (xv) GAP (Bermuda) LP owned of record no ordinary shares or 0.0% of the issued and outstanding ordinary shares

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 20 of 26

     

     

    GA PH is a wholly owned subsidiary of GA Coop UA. The GA Funds and the Sponsor Coinvestment Funds share beneficial ownership of the shares of common stock held of record by GA PH. The general partner of GAP Lux is GA GenPar Lux and the general partner of GA GenPar Lux is GA Lux. The general partner of GAP Bermuda IV and GAP Bermuda EU and the sole shareholder of GA Lux is GenPar Bermuda. GAP (Bermuda) LP, which is controlled by the management committee of GASC MGP, LLC (the “GA Management Committee”), is the general partner of GenPar Bermuda and GA Coop LP. GA LP, which is also controlled by the GA Management Committee, is the managing member of GAPCO III, GAPCO IV and GAPCO V and the general partner of GAPCO CDA. As of the date hereof, there are eleven members of the GA Management Committee. By virtue of the foregoing, the Reporting Persons may be deemed to share voting power and the power to direct the disposition of the shares that each owns of record. Each of the members of the GA Management Committee disclaims ownership of the ordinary shares reported herein except to the extent that he has a pecuniary interest therein. The name, the address and the citizenship of each of the members of the GA Management Committee as of the date hereof is attached hereto as Schedule A and is hereby incorporated by reference.

    Amount Beneficially Owned:

    By virtue of the relationship described above, each of the Reporting Persons may be deemed to beneficially own 7,531,252 ordinary shares.

    Percentage Owned:

    All calculation of percentage ownership herein are based on an aggregate of 53,483,675 ordinary shares, consisting of 52,108,675 ordinary shares represented by the Company to be outstanding as of December 8, 2023 at the closing of the offering contemplated in the Prospectus Supplement filed with the Securities and Exchange Commission on December 7, 2023, pursuant to Rule 424(b)(5), and 1,375,000 ordinary shares that would result from the exercise of pre-funded warrants issued to GA PH in the same offering. In connection with such offering, GAP Bermuda IV filed a notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) with the U.S. Federal Trade Commission and the U.S. Department of Justice. On January 23, 2024, the applicable waiting period pursuant to the HSR Act expired. GA PH exercised the pre-funded warrants on January 25, 2024.

    Number of Shares as to Which Such Person Has Sole/Shared Power to Vote or to Direct the Vote and Sole/Shared Power to Dispose or to Direct the Disposition of:

    (i)Each of the Reporting Persons may be deemed to have the sole power to direct the voting and dispositions of the ordinary shares as indicated on such Reporting Person’s cover page included herein.
    (ii)Each of the Reporting Persons may be deemed to share the power to direct the voting and dispositions of the ordinary shares that may be deemed to be owned beneficially by each of them as indicated on such Reporting Person’s cover page included herein.
    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable.

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 21 of 26

     

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    See Item 2, which states the identity of the members of the group filing this Schedule 13G.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable.

     

    Item 10. CERTIFICATION

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 22 of 26

     

     

    Exhibit Index

     

    Exhibit 1.

    Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (previously filed).

     

     

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 23 of 26

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated as of February 13, 2024

     

      GENERAL ATLANTIC, L.P.  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
             
      GENERAL ATLANTIC PH B.V.  
             
      By: /s/ I.M. van der Hoorn  
        Name: I.M. van der Hoorn  
        Title: Director A  
             
      By: /s/ J.V. Lepeltak  
        Name: J.V. Lepeltak  
        Title: Director B  
             
      GENERAL ATLANTIC COÖPERATIEF U.A.  
           
      By: /s/ I.M. van der Hoorn  
        Name: I.M. van der Hoorn  
        Title: Director A  
             
      By: /s/ J.V. Lepeltak  
        Name: J.V. Lepeltak  
        Title: Director B  
             
      GENERAL ATLANTIC PARTNERS (BERMUDA) IV, L.P.  
             
      By: GENERAL ATLANTIC GENPAR (BERMUDA), L.P., its general partner  
             
      By: GAP (BERMUDA) L.P., its general partner  
     

     

    By:

     

    GAP (BERMUDA) GP LIMITED, its general partner

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 24 of 26

     

     

      GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.  
             
      By: GENERAL ATLANTIC GENPAR (BERMUDA), L.P., its general partner  
             
      By: GAP (BERMUDA) L.P., its general partner  
           
      By: GAP (BERMUDA) GP LIMITED, its general partner  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
             
      GENERAL ATLANTIC PARTNERS (LUX) SCSP  
             
      By: GENERAL ATLANTIC GENPAR (LUX) SCSP, its general partner  
             
      By: GENERAL ATLANTIC (LUX) S.À R.L.  
             
      By: /s/ Ingrid van der Hoorn  
        Name: Ingrid van der Hoorn  
        Title: Manager A  
             
      By: /s/ William Blackwell  
        Name: William Blackwell  
        Title: Manager B  
         
      GENERAL ATLANTIC COÖPERATIEF, L.P.  
             
      By: GAP (BERMUDA) L.P., its general partner  
           
      By: GAP (BERMUDA) GP LIMITED, its general partner  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 25 of 26

     

     

      GAP COINVESTMENTS III, LLC  
             
      By: GENERAL ATLANTIC, L.P., its managing member  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
             
      GAP COINVESTMENTS IV, LLC  
             
      By: GENERAL ATLANTIC, L.P., its managing member  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
             
      GAP COINVESTMENTS V, LLC  
             
      By: GENERAL ATLANTIC, L.P., its managing member  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
         
      GAP COINVESTMENTS CDA, L.P.  
             
      By: GENERAL ATLANTIC, L.P., its general partner  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  

     

       

     

     

    CUSIP No. N69605108 SCHEDULE 13G Page 26 of 26

     

     

      GENERAL ATLANTIC GENPAR, (LUX) SCSP  
             
      By:

    GENERAL ATLANTIC (LUX)

    S.À R.L.

     
             
      By: /s/ Ingrid van der Hoorn  
        Name: Ingrid van der Hoorn  
        Title: Manager A  
             
      By: /s/ William Blackwell  
        Name: William Blackwell  
        Title: Manager B  
             
      GENERAL ATLANTIC (LUX) S.À R.L.  
             
      By: /s/ Ingrid van der Hoorn  
        Name: Ingrid van der Hoorn  
        Title: Manager A  
             
      By: /s/ William Blackwell  
        Name: William Blackwell  
        Title: Manager B  
         
      GENERAL ATLANTIC GENPAR (BERMUDA), L.P.  
             
      By: GAP (BERMUDA) L.P., its general partner  
           
      By: GAP (BERMUDA) GP LIMITED, its general partner  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  

     

      GAP (BERMUDA) L.P.    
         
      By: GAP (BERMUDA) GP LIMITED, its general partner  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  

     

       

     

     

    SCHEDULE A

     

    Members of the GA Management Committee (as of the date hereof)

     

    Name Address Citizenship

    William E. Ford

    (Chief Executive Officer)

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Gabriel Caillaux

    23 Savile Row

    London W1S 2ET

    United Kingdom

    France
    Andrew Crawford

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Martin Escobari

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    Bolivia and Brazil
    Anton J. Levy

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Sandeep Naik

    Marina Bay Financial Centre Tower 1

    8 Marina Boulevard, #17-02

    018981, Singapore

    United States
    J. Albert Smith

    535 Madison Ave,

    31st Floor

    New York, New York 10022

    United States
    Graves Tompkins

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Lance D. G. Uggla

    23 Savile Row

    London W1S 2ET

    United Kingdom

    United Kingdom and Canada
    N. Robbert Vorhoff

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Eric Zhang

    Suite 5704-5706, 57F

    Two IFC, 8 Finance Street

    Central, Hong Kong, China

    Hong Kong SAR

     

     

       

     

    Get the next $PHVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHVS

    DatePrice TargetRatingAnalyst
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    9/25/2023$27.00Outperform
    Wedbush
    8/15/2023$10.00 → $34.00Equal-Weight → Overweight
    Morgan Stanley
    10/5/2022$16.00Buy
    Bryan Garnier
    9/13/2022$34.00 → $18.00Mkt Outperform
    JMP Securities
    8/23/2022$40.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    8/22/2022$26.00 → $13.00Neutral → Underperform
    BofA Securities
    5/25/2022$34.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $PHVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pharvaris N.V. with a new price target

      Cantor Fitzgerald initiated coverage of Pharvaris N.V. with a rating of Overweight and set a new price target of $28.00

      4/29/25 8:11:22 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Pharvaris N.V. with a new price target

      Wedbush initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $27.00

      9/25/23 7:40:10 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris N.V. upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Pharvaris N.V. from Equal-Weight to Overweight and set a new price target of $34.00 from $10.00 previously

      8/15/23 7:24:38 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PHVS
    Financials

    Live finance-specific insights

    See more

    $PHVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PHVS
    SEC Filings

    See more
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/14/24 8:42:52 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/14/24 10:27:18 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/13/24 2:14:59 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

      CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

      9/5/24 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

      Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

      12/6/23 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

      Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings. RAPIDe-1 Clinical Stu

      12/8/22 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedemaData presented at recent congresses reinforces the value of deucrictibant by highlighting its ability to maintain a reduced attack rate in long-term prophylaxis, and potential to rapidly and completely treat HAE attacks, including in participants experiencing upper-ai

      4/7/25 6:58:03 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

      ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. The U.S. Food and Drug Administration (FDA) previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in M

      4/1/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

      Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of lifeOngoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time to onset of symptom relief was 0.9 hours (N=7)In both extension studies, deucrictibant was generally well tolerated with no safety signals observed ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradyki

      3/3/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      4/7/25 6:51:03 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Pharvaris N.V.

      20-F - Pharvaris N.V. (0001830487) (Filer)

      4/7/25 6:50:27 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      1/13/25 6:51:02 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

      ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

      11/15/23 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

      Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for RAPIDe-1, a global Phase 2 study of PHVS416 for the acute treatment of HAE attacks ongoing outside the U.S.Executing from a strong financial position with cash and cash equivalents of €201 million as of June 30, 2022 ZUG, Switzerland, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the second quarter ended June 30, 2022, and provided a business update

      9/12/22 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care